On October 22, Maccura Biotechnology (300463.SZ) announced that with the clear positioning of the company's global strategy and changes in the market environment, in order to further focus on core business, optimize resource allocation, enhance the company's market competitiveness and operational quality, accelerate the adjustment of regional direct sales and dealer business. Maccura Biotechnology Co., Ltd. intends to transfer all 60% of the equity of its controlling subsidiary Inner Mongolia Maccura Biotechnology Co., Ltd. (hereinafter referred to as 'Inner Mongolia Maccura') to Meishidian at an initial transaction price of RMB 23.9401 million.
After the completion of this equity transfer, the company will no longer hold equity in Inner Mongolia Maccura, no longer include Inner Mongolia Maccura in the company's consolidated financial statements scope, establish an office in Inner Mongolia, and manage and expand regional dealers through the office, continue to cover and expand the Inner Mongolia regional market. This equity transfer will not have a significant impact on the company's core business operation.
